Drug Trial Radar · NCT07053345
A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression
Last checked: Nov 20, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
47
Actual
Start
Jun 9, 2025
Primary completion
Jul 13, 2026
Study completion Jul 13, 2026
Sponsor
- Lead sponsor
- Janssen Korea, Ltd., KoreaJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jul 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate how well esketamine nasal spray works in improving depressive symptoms in participants with treatment resistant depression (TRD). This will be assessed by the change from baseline in the Hamilton depression rating scale (HAM-D; 17-item) total score from Day 1 (baseline) to the end of the 4-week treatment phase (Day 28).
Conditions
- Depressive Disorder, Treatment-Resistant
Interventions
Esketamine 56 mgDrug
Participants will self-administer 56 mg of esketamine as intranasal spray into each nostril.
Esketamine 84 mgDrug
Participants will self-administer 84 mg of esketamine as intranasal spray into each nostril.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Day 28 in Hamilton Depression Rating Scale (HAM-D) Total ScoreTime frame: Baseline up to Day 28
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Cha Ilsan Medical Center
Goyang Si Gyeonggi Do, South Korea
Wonkwang University Hospital
Iksan, South Korea
Kangbuk Samsung Hospital
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Kyung Hee University Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.